US Patent Issued to Cephalon on Sept. 9 for "Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases" (Australian Inventors)

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,410,256, issued on Sept. 9, was assigned to Cephalon LLC (West Chester, Pa.).

"Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases" was invented by Lynn Dorothy Poulton (Macquarie Park, Australia), Adam Clarke (Five Dock, Australia), Andrew James Pow (Pascoe Vale, Australia), Debra Tamvakis (Camberwell, Australia), George Kopsidas (Preston, Australia), Anthony Gerard Doyle (Drummoyne, Australia), Philip Anthony Jennings (Warrawee, Australia) and Matthew Pollard (Dural, Australia).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an ...